News Archive

Faculty from the Duke Clinical Research Institute (DCRI) shared new research and offered expert perspectives on emerging issues and advancements in cardiovascular care as part of more than 45 sessions during the American College of Cardiology (ACC) Scientific Sessions, held March 29-31 in Chicago.

Five years after the start of the COVID-19 pandemic, the research community is reflecting on the historic research response to understand the disease and develop diagnostics, therapies, and vaccines. In a special thematic issue of the Journal of Clinical and Translational Science, a set of papers outlines the most critical takeaways for the public health and research communities that should be applied to future public health emergencies.

Leading experts recently explored how generative AI could revolutionize clinical research through automated documentation and enhanced trial efficiency. Their findings, published in JACC: Advances, outline crucial steps for successful AI integration while addressing technical, ethical, and regulatory challenges to ensure more inclusive and equitable research outcomes.

A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit in taking metformin at a titrated dosage of 1,500 mg per day for 14 days for the treatment of mild-to-moderate COVID-19 symptoms.

The Duke Clinical Research Institute (DCRI) has launched its new podcast, "Beyond the Endpoint," aimed at demystifying clinical research and healthcare through engaging conversations with renowned clinicians and scientists. The podcast debuted on Wednesday, Jan. 15, and provides personal and expert perspectives on the latest gold-standard research and real-world evidence, making complex topics accessible to a broad audience.

Cytokinetics, Incorporated today announced that COMET-HF (Confirmation of Omecamtiv Mecarbil Efficacy Trial in Heart Failure), a Phase 3 clinical trial of omecamtiv mecarbil in patients with symptomatic heart failure (HF) with severely reduced ejection fraction, is open to enrollment. Omecamtiv mecarbil is a novel investigational selective cardiac myosin activator in development for the potential treatment of heart failure with severely reduced ejection fraction. COMET-HF is being conducted in collaboration with Duke Clinical Research Institute (DCRI).

i-Cubed, Duke Clinical Research Institute’s (DCRI) center for clinical research innovation, is partnering with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, for BARDA’s Decentralized Clinical Operations for Healthcare and Research (D-COHRe) program to enhance decentralized clinical trial (DCT) capabilities to address public health emergencies (PHEs).

Faculty experts from the Duke Clinical Research Institute shared new research results, provided thought-provoking insights, and championed therapeutic guidelines and best practices as part of more than 40 sessions during the 2024 American Heart Association (AHA) Scientific Sessions.

Duke Clinical Research Institute (DCRI) faculty member Laura Schanberg, MD, was recently honored with the American College of Rheumatology (ACR) Master Designation during the College’s annual meeting, Convergence, 2024. The honor is an Award of Merit from the Association of Rheumatology Professionals (ARP) and reflects Schanberg’s outstanding contributions to the advancement of rheumatology.

Some 37 million people in the U.S. – more than one in seven adults – have chronic kidney disease (CKD). But not everyone faces the same risk. A new research consortium led by the Duke Clinical Research Institute and the Samuel DuBois Cook Center on Social Equity focuses on addressing the striking disparities in kidney health linked to structural racism.